I'll research EMR (Emerson Electric) before writing the preview. Let me gather recent filings, transcripts, and news.I'll read the most recent earnings materials and the investor day, plus check news and price action.Let me get the investor day highlights, recent stock price action, and any late-July news.Let me check recent news/context around EMR and peers heading into the print.# Emerson Electric (EMR) — Q3 FY2026 Earnings Preview Report date: Tuesday, August 4, 2026 (after close) | Quarter: Fiscal Q3 2026 (ended June 30, 2026)
Emerson enters this print as a re-rated, transformation-complete "global automation leader" story, with shares running hard into the quarter. The key debate is whether order momentum and the growth-vertical secular story (power, LNG, life sciences, semis, A&D) are strong enough to (a) confirm the second-half acceleration management has promised and (b) justify a stock that has moved sharply higher over the past two weeks.
EMR closed at $154.88 on Aug 3, near the top of its recent range and up roughly +13% in the two weeks from the July 20 low (~$136.58). That extends a recovery from the early-April low (~$132). In short, expectations are elevated and positioning looks constructive — the bar for a "clean beat-and-raise" is higher than it was a month ago.
For context, peers have been volatile into the industrial earnings season (e.g., Eaton and Rockwell also swung meaningfully in late July), so read-throughs on short-cycle demand, power/data-center capex, and process automation will color the reaction.
| Metric | Q3 FY2026 Guide | Full-Year FY2026 Guide |
|---|---|---|
| Net sales growth | ~5.5% | ~4.5% |
| Underlying sales growth | ~5% | ~3% |
| Adj. segment EBITDA margin | ~28% | ~28% |
| Adjusted EPS | $1.65–$1.70 | $6.45–$6.55 |
| GAAP EPS | $1.22–$1.27 | $4.79–$4.89 |
| Free cash flow | — | $3.5B–$3.6B |
| Operating cash flow | — | $4.0B–$4.1B |
Segment-level Q3 growth framework management laid out on the Q2 call: - Software & Systems: ~+8% (Test & Measurement mid-teens; Control Systems & Software mid-single-digit) - Intelligent Devices: ~+4% - Safety & Productivity: ~+1%
FY expectations by group: Software & Systems ~+5%, Test & Measurement raised to low-teens (from prior high-single-digit), Intelligent Devices lowered to ~+2% (Middle East drag), Safety & Productivity ~+2%.
Management is explicitly guiding H2 to accelerate (underlying growth stepping from ~3% in Q2 to ~5% in Q3). That plan rests on a backlog of $8.2B, up 9% y/y, a Q2 book-to-bill of 1.07, and underlying orders +5% in Q2. Watch whether Q3 underlying orders hold the ~mid-single-digit pace against tougher comps — management said mid-single-digit orders are "sustainable" and set up the first half of FY2027. Any order deceleration would undercut the H2/FY27 ramp thesis.
The Q2 miss on underlying sales (+0.5% vs. plan) was driven by an ~1-point hit from the Middle East conflict, and management baked a full-year 1-point headwind into guidance. Key facts to update: - ~$50M of disruption in Q2, with ~$100M more assumed across the balance of the year. - Customer sites running at ~75% capacity; field service engineers back to ~80% of pre-conflict levels. - A ~$100M rebuild/restart opportunity identified across 47 damaged sites, expected to play out over ~6 quarters (with potentially much larger — but unquantified — upside if LNG/downstream capacity is rebuilt).
Watch: is the region tracking to (or better than) the assumed recovery, and does the Strait of Hormuz logistics situation keep improving? This is the single biggest swing factor for near-term revenue and the segment mix.
Annual contract value grew 9% in Q2 to $1.64B, with management reaffirming 10%+ ACV growth for FY2026. Two things to track: - The "software contract renewal dynamic" — a self-created headwind that hit Q2 sales by ~2 pts, margin by ~90 bps, and EPS by ~$0.09; it reverses and becomes a slight tailwind in FY27. Watch how much it still weighs on H2 optics. - AI positioning. Management is leaning hard into the argument that its industrial software (AspenTech, DeltaV, Ovation, NI's Nigel) is defensible vs. AI disruption because it's built on first-principle models and mission-critical, regulated workflows. Any commentary on AI monetization/tiering and adoption from the recent AspenTech OPTIMIZE and NI Connect user conferences is a potential catalyst — though management flagged AI revenue is "a little early" to be meaningful, with the bigger impact in FY27+.
Q2 adjusted segment EBITDA margin was 27.6% (ahead of plan on favorable mix and price/cost), and management is holding ~28% for the full year with 40%+ incrementals ex-items. Tariffs are assumed net-neutral (IEEPA removal offset by Section 232/122 and freight). Watch for: price realization holding above net material inflation (including memory/chip cost pressure), and whether H2 project mix pressures margins as backlog converts.
Management set hard 2028 targets that this quarter is implicitly measured against: $21B revenue, 30% adj. segment EBITDA margin, $8 adjusted EPS, $12B cumulative FCF, 20% FCF margin, and ~$10B returned to shareholders (2026–28) — anchored on 4–7% through-cycle organic growth and 40%+ incrementals. The buyback ramps meaningfully in FY27–28 ($2.5B/yr), so any signal on when Emerson pivots harder to shareholder returns matters.
Net: the fundamentals and secular story remain strong, but with shares up ~13% in two weeks and near the high end of the range, this is a "prove the second-half ramp and the Middle East recovery" quarter. Orders, ACV, and any FY EPS raise are the three data points to anchor on.
Note: I was unable to retrieve fresh news-flow from the days immediately preceding the print, so this preview is built from Emerson's Q2 FY2026 results/guidance (reported May 5, 2026), the November 2025 Investor Day, and recent price action. Confirm against any last-minute pre-announcements or sell-side notes.